Targeting IL-13 in Moderate to Severe Atopic Dermatitis: Forging a New Path to Improved Disease and Patient Outcomes

Atopic dermatitis (AD) significantly impacts physical, social, and psychological well-being. Recently, novel, more effective treatment options have been approved, including those targeting interleukin-13. Watch this webcast for expert insights on incorporating these agents to optimize care for patients with moderate to severe AD.

Share

Program Content

Activities

Targeting IL-13 for AD Care
Targeting IL-13 in Moderate to Severe Atopic Dermatitis: Forging a New Path to Improved Disease and Patient Outcomes
Video
Congratulations: You achieved a completion on 04/09/2022

Released: May 15, 2023

Expires: May 14, 2024

Activities

Targeting IL-13 for AD Slides
Slides on Targeting IL-13 in Moderate to Severe Atopic Dermatitis: Forging a New Path to Improved Disease and Patient Outcomes
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 10, 2023

Activities

IL-13 Inhibitors for AD CT
Expert Commentary on the Use of IL-13 Inhibition in Treating Moderate to Severe Atopic Dermatitis
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: May 19, 2023

Provided by

ProCE Banner

Provided by Partners for Advancing Clinical Education (PACE)

Supporters

This activity is supported by an educational grant from Lilly.

Lilly